Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial.
Minas P. Economides(NYU Langone Health), Scot A. Niglio(National Cancer Institute), Tsivia Hochman(NYU Langone Health), Sean P. Pitroda(University of Chicago), James Wysock(New York University), Ajjai Alva(Michigan Medicine), Marisa Kollmeier(Memorial Sloan Kettering Cancer Center), Jonathan E. Rosenberg(Memorial Sloan Kettering Cancer Center), Gary D. Steinberg(Rush University Medical Center), William C. Huang(NYU Langone Health), Samir S. Taneja(NYU Langone Health), Arjun Vasant Balar(NYU Langone Health), Tracy L. Rose(University of North Carolina at Chapel Hill), David R. Wise, Matthew I. Milowsky(UNC Lineberger Comprehensive Cancer Center), Peter B. Schiff(NYU Langone Health), Judith D. Goldberg(New York University), Nicholas J Sanfilippo(NYU Langone Health), Peter H. O’Donnell(University of Chicago)
Cited by 8
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2017|1.3k
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
|JAMA Oncology|2017|846